A PIPELINE POWERED BYPASSION
PUBLICATIONS AND PRESENTATIONS
The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (COSMIC-HF)
Poster, Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting 2020
Virtual Online
October 2020
Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction, GALACTIC‐HF: Baseline Characteristics and Comparison with Contemporary Clinical Trials
European Journal of Heart Failure
Teerlink JR, Diaz R, Felker GM, McMurray JJ, Metra M, Solomon SD, Adams KF, Anand I, Arias‐Mendoza A, Biering‐Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo‐Leiro, MG, Dahlström U, Diaz R, Echeverria Correa LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Lund M, Macdonald P, Mareev V, Momomura Si, O’Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Abbasi SA, Varin C, Malik FI, Kurtz CE
September 27, 2020
Clinical Implications of MiToS in ALS Patients Using FORTITUDE-ALS Data for 12 Weeks Follow Up
Poster, American Academy of Neurology 2020
Virtual Online
May 2020
CV Outcomes Trial for Omecamtiv Mecarbil Enrolls 8,256 Patients With HFrEF
Poster, American College of Cardiology & World Congress of Cardiology 2020 (ACC.20/WCC)
Virtual Online
March 28, 2020
The novel myotrope, AMG 594, is a small-molecule cardiac troponin activator that increases cardiac contractility in vitro and in vivo
Poster, Keystone Symposium: Charting a New Course for Heart Failure: From Discovery to Data
Keystone, Colorado
March 3, 2020